A DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTRE, RANDOMISED PHASE III STUDY OF DISEASE-RELATED SYMPTOMS COMPARING ZD1839 (IRESSA)(250MG TABLET) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN SYMPTOMATIC PATIENTS WITH ADVANCED NSCLC WHO HAVE RECEIVED ONE OR TWO PRIOR CHEMOTHERAPY REGIMENS AND ARE REFRACTORY OR INTOLERANT TO THEIR MOST RECENT REGIMENS

*Please Note* The Study information you are attempting to view is not available on ClinicalTrials.gov as the Study predates the Food and Drug Administration Amendments Act (FDAAA), Section 801 requirements. More information regarding this study may be available by contacting [email protected].

*Please Note* The Study information you are attempting to view is not available on ClinicalTrials.gov as the Study predates the Food and Drug Administration Amendments Act (FDAAA), Section 801 requirements. More information regarding this study may be available by contacting [email protected].